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Table Excluded studies and reasons for exclusion (n=748)  
Reference Reason for exclusion 
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. 
Memantine in patients with Parkinson's disease dementia or dementia with 
Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet 
Neurology 2009;8(7):613-8 
 
Not a disease 
modification trial 
AbbVie. NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal 
Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild 
Alzheimer's Disease and Mild Cognitive Impairment. URL: 
https://clinicaltrials.gov/ct2/show/NCT02573740 Accessed 29th January 2016 
No quantitative outcome 
relating to disease 
modification 
Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients 
with probable Alzheimer's disease. Neurology 2001;57(8):1515-7 
 
Not a disease 
modification trial 
Adami M, Scarpini E, Bruno G, Zappala G, Richarz U, Gaudig M, et al. Cessation 
versus continuation of 12 months galantamine therapy in patients with 
Lzheimer's disease: A randomised, double blind, placebo controlled withdrawal 
trial. Alzheimers Dement 2011;1:S794 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Adamus WS, Leonard JP, Tröger W. Phase I clinical trials with WAL 2014, a new 
muscarinic agonist for the treatment of Alzheimer's disease. Life sciences 
1995;56(11):883-90 
 
No participants with mild 
or moderate dementia 
Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of 
rivastigmine in patients with dementia of the Alzheimer type. Current 
Therapeutic Research - Clinical and Experimental 1998;59(12):837-45 
 
Not a disease 
modification trial 
Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of 
rivastigmine, donepezil and galantamine in a real-world setting. Current 
medical research and opinion 2004;20(11):1747-52 
 
Not a disease 
modification trial 
Aguiar P, Monteiro L, Feres A, Gomes I, Melo A. Rivastigmine transdermal 
patch and physical exercises for Alzheimer's disease: a randomized clinical trial. 
Current Alzheimer Research 2014;11(6):532-7 
 
Not a disease 
modification trial 
Aguirre E, Spector A, Hoe J, Russell IT, Knapp M, Woods RT, et al. Maintenance 
Cognitive Stimulation Therapy (CST) for dementia: a single-blind, multi-centre, 
randomized controlled trial of Maintenance CST vs. CST for dementia. Trials 
2010;11:46 
 
Not a disease 
modification trial 
Ahlin A, Nyback H, Junthe T, Ohman G, Nordgren I. Tetrahydroaminoacridine in 
Alzheimer's dementia: Clinical and biochemical results of a double-blind 
crossover trial. Human Psychopharmacology 1991;6(2):109-18 
 
Not a disease 
modification trial 
Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus 
high frequencies of repetitive transcranial magnetic stimulation on cognitive 
function and cortical excitability in Alzheimer's dementia. Journal of Neurology 
2012;259(1):83-92 
 
Not a disease 
modification trial 
Reference Reason for exclusion 
Akanuma K, Meguro K, Meguro M, Sasaki E, Chiba K, Ishii H, et al. Improved 
social interaction and increased anterior cingulate metabolism after group 
reminiscence with reality orientation approach for vascular dementia. 
Psychiatry Research 2011;192(3):183-7 
 
Not a disease 
modification trial 
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani 
M. Melissa officinalis extract in the treatment of patients with mild to 
moderate Alzheimer's disease: a double blind, randomised, placebo controlled 
trial. Journal of Neurology, Neurosurgery & Psychiatry 2003;74(7):863-6 
 
Not a disease 
modification trial 
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani 
M. Salvia officinalis extract in the treatment of patients with mild to moderate 
Alzheimer's disease: a double blind, randomized and placebo-controlled trial. 
Journal of Clinical Pharmacy & Therapeutics 2003;28(1):53-9 
 
Not a disease 
modification trial 
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine 
transdermal patch on activities of daily living: item responder analyses. 
International Journal of Geriatric Psychiatry 2011;26(4):356-63 
 
Not a disease 
modification trial 
Alva G, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M. Efficacy of 
higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's 
Disease Assessment Scale-cognitive subscale: Domain and individual item 
analysis. International journal of geriatric psychiatry 2014;29(9):920-7 
 
Not a disease 
modification trial 
Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, et 
al. Combination treatment in Alzheimer's disease: results of a randomized, 
controlled trial with cerebrolysin and donepezil. Current Alzheimer research 
2011;8(5):583-91  
 
Not a disease 
modification trial 
Alvarez A, Iglesias O, Aleixandre M, Linares C, Figueroa J, Muresanu D, et al. 
Cerebrolysin and combination therapy enhance serum bdnf in ad patients. 
Alzheimer's & dementia 2014;10:774 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: 
association between the cholinesterase inhibitor donepezil and the cholinergic 
precursor choline alphoscerate in Alzheimer's disease with cerebrovascular 
injury: interim results. Journal of the neurological sciences 2012;322(1-2):96-
101 
 
Not a disease 
modification trial 
Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal 
fluid acetylcholinesterase activity after long-term treatment with donepezil 
and rivastigmina. Mechanisms of Ageing and Development 2001;122(16):2057-
62 
 
Not a disease 
modification trial 
Amieva H, Dartigues JF. ETNA3, a clinical randomized study assessing three 
cognitive-oriented therapies in dementia: rationale and general design. Revue 
Neurologique 2013;169(10):752-6 
 
Not a disease 
modification trial 
Andersen F, Viitanen M, Halvorsen DS, Straume B, Wilsgaard T, Engstad TA. 
The effect of stimulation therapy and donepezil on cognitive function in 
Alzheimer's disease. A community based RCT with a two-by-two factorial 
design. BMC Neurology 2012;12:59 
 
Not a disease 
modification trial 
Andrade LP, Gobbi LT, Coelho FG, Christofoletti G, Costa JL, Stella F. Benefits of 
multimodal exercise intervention for postural control and frontal cognitive 
Not a disease 
modification trial 
Reference Reason for exclusion 
functions in individuals with Alzheimer's disease: a controlled trial. Journal of 
the American Geriatrics Society 2013;61(11):1919-26 
 
Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of 
the combination of memantine plus vitamin D on cognition in patients with 
Alzheimer disease: a pre-post pilot study. Cognitive and Behavioral Neurology 
2012 ;25(3):121-7 
 
Not a randomised 
controlled trial/clinical 
controlled trial 
Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-
effectiveness of memantine in community-based Alzheimer's disease patients: 
An adaptation in Spain European Journal of Health Economics 2006;7(2):137-44 
 
Not a disease 
modification trial 
Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The 
effects of combine treatment of memantine and donepezil on Alzheimer's 
disease patients and its relationship with cerebral blood flow in the prefrontal 
area. International Journal of Geriatric Psychiatry 2014;29(9):881-9 
 
Not a disease 
modification trial 
Arcoverde C, Deslandes A, Moraes H, Almeida C, Araujo NB, Vasques PE, et al. 
Treadmill training as an augmentation treatment for Alzheimer's disease: A 
pilot randomized controlled study. Arquivos de neuro-psiquiatria 
2014;72(3):190-6 
 
Not a disease 
modification trial 
Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A. Effect of one-year vitamin C- 
and E-supplementation on cerebrospinal fluid oxidation parameters and 
clinical course in Alzheimer's disease. Neurochemical Research 
2012;37(12):2706-14 
 
Not a disease 
modification trial 
Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of 
galantamine in patients with mild or moderate Alzheimer's disease: post Hoc 
analysis of a randomized, double-blind, placebo-controlled trial. Drugs & Aging 
2009;26(3):231-9 
 
Not a disease 
modification trial 
Arrigo A, Moglia A, Borsotti L. A double-blind, placebo-controlled, crossover 
trial with nicergoline in patients with senile dementia. International Journal of 
Clinical Pharmacology Research 1982;2(4 Suppl. 1):33-41 
 
Not a disease 
modification trial 
Ash E, Bregman N, Moore O, Korczyn A, Zangen A. Transcranial magnetic 
stimulation of deep brain regions in Alzheimer's disease. Alzheimer's & 
dementia 2014;10:P450  
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Ash EL, Vakhapova V, Bova I, Simon E, Korem M, Eldad M, et al. Transcranial 
magnetic stimulation of deep brain regions in Alzheimer's disease: A pilot 
study. Annals of Neurology 2012;72:S126 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, et al. MR 
spectroscopy for assessment of memantine treatment in mild to moderate 
Alzheimer dementia. Journal of Alzheimer's Disease 2011;26(SUPPL. 3):331-6 
 
Not a disease 
modification trial 
Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, et al. Verbal repetition in 
patients with Alzheimer's disease who receive donepezil. International Journal 
of Geriatric Psychiatry 2006;21(5):426-31 
 
Not a disease 
modification trial 
Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, et al. High-
dose estradiol improves cognition for women with AD: results of a randomized 
study. Neurology 2001;57(4):605-12 
Not a disease 
modification trial 
Reference Reason for exclusion 
 
Atri A, Hendrix S, Pejovic V, Graham S. Extended-release daily memantine 
provides increasing cumulative benefits across clinical domains over 24 weeks 
in patients with moderate to severe Alzheimer's disease: An analysis of area 
under the curve. Neurology 2014;1 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in 
patients with Alzheimer's disease receiving donepezil: New analyses of efficacy 
and safety for combination therapy. Alzheimer's research & therapy 2013;5(1) 
 
Not a disease 
modification trial 
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term Course and 
Effectiveness of Combination Therapy in Alzheimer Disease. Alzheimer Disease 
& Associated Disorders 2008;22(3):209-21 
 
Not a disease 
modification trial 
Auchus A, Brashear H, Salloway S, Korczyn A, De Deyn P, Gassmann-Mayer C. 
Galantamine treatment of vascular dementia: A randomized trial. Neurology 
2007;69(5):448-58 
 
Not a disease 
modification trial 
Avila R, Carvalho IA, Bottino CM, Miotto EC. Neuropsychological rehabilitation 
in mild and moderate Alzheimer's disease patients. Behavioural neurology 
2007;18(4):225-33 
 
Not a disease 
modification trial 
Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. Propentofylline treatment 
for Alzheimer disease and vascular dementia: an economic evaluation based 
on functional abilities. Alzheimer Disease & Associated Disorders 
2000;14(2):102-11 
 
Not a disease 
modification trial 
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate 
Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 
6-month study. Journal of Alzheimer's disease 2007;11(4):471-9 
 
Not a disease 
modification trial 
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten ECW, et al. 
Efficacy, safety and tolerability of rivastigmine capsules in patients with 
probable vascular dementia: The VantagE study. Current Medical Research and 
Opinion 2008;24(9):2561-74 
 
Not a disease 
modification trial 
Ban TA, Morey LC, Aguglia E, Batista R, Campanella G, Conti L, et al. 
Glycosaminoglycan polysulfate in the treatment of old age dementias. Progress 
in neuro-psychopharmacology & biological psychiatry 1991;15(3):323-42 
 
Not a disease 
modification trial 
Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH. Inositol treatment of 
Alzheimer's disease: A double blind, cross-over placebo controlled trial. 
Progress in Neuro-Psychopharmacology & Biological Psychiatry 
1996;20(4):729-36 
 
Not a disease 
modification trial 
Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus 
placebo in hyperhomocysteinemic Parkinson's disease dementia patients. 
Movement Disorders 2008;23(11):1532-40 
 
Not a disease 
modification trial 
Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-
controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dementia 
and geriatric cognitive disorders 2000;11(4):230-7 
 
Not a disease 
modification trial 
Reference Reason for exclusion 
Batman MW. The effects of therapeutic aquatic exercise on patients with 
Alzheimer's Disease. (elderly) Dissertation Abstracts International: Section B: 
The Sciences and Engineering 1999;60(6-B):2933 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Battaglia A, Annon K, Pamparana F, De Paolis C, Bonura ML, Stekke W et al. P-
8-11 Nicergoline in the long term treatment of mild or moderate senile 
dementia. A multicenter double-blind, randomized, placebo-controlled trial. 
European Neuropsychopharmacology 1995;5(3):383 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Baum L, Lam CWK, Cheung SKK, Kwok T, Lui V, Tsoh J, et al. Six-month 
randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in 
patients with Alzheimer disease. Journal of Clinical Psychopharmacology 
2008;28(1):110-3 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Bayer AJ, Bokonjic R, Booya NH, Demarin V, Ersmark B, Fairbairn AF, et al. 
European pentoxifylline multi-infarct dementia study. European Neurology 
1996;36(5):315-21 
 
Not a disease 
modification trial 
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-
blind, placebo-controlled study of metrifonate, an acetylcholinesterase 
inhibitor, for Alzheimer disease. Alzheimer Disease & Associated Disorders 
1996;10(3):124-31 
 
Not a disease 
modification trial 
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Effects of 
metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-
controlled, 6-month study. Alzheimer Disease & Associated Disorders 
1998;12(1):54-7 
 
Not a disease 
modification trial 
Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the 
progression of cognitive decline in Alzheimer's disease using mifepristone. 
Journal of molecular neuroscience 2002;19(1-2):201-6 
 
Not a disease 
modification trial 
Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary 
degenerative dementia. A double-blind study of response to different dose 
level. Psychopharmacology 1985;87(2):147-51 
 
Not a disease 
modification trial 
Bentham PW. A double-blind placebo-controlled trial of L-tryptophan to assess 
the degree of cognitive and behavioural improvement in patients with 
Alzheimer-type dementia and to compare differential response in clinical sub-
groups. International Clinical Psychopharmacology 1990;5(4):261-72 
 
Not a disease 
modification trial 
Bergamaschini LC, Scarpini E, Rossi E, Galimberti D, Case A, Lucca U, et al. 
[Randomised pilot study on the feasibility of Enoxaparin treatment in 
Alzheimer's disease]. Neurodegenerative Diseases 2011;8 
 
Full text unavailable in 
English 
Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the 
treatment of cognitive impairment in patients with dementia of the Alzheimer 
type. Functional Neurology 1994;9(3):161-8 
 
Not a disease 
modification trial 
Bergamasco B, Villardita C, Coppi R. Idebenone in the treatment of multi-
infarct dementia: A randomised, double-blind, placebo controlled multicentre 
trial. Archives of Gerontology and Geriatrics 1992;15(3):271-8 
 
Not a disease 
modification trial 
Reference Reason for exclusion 
Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW. 
Donepezil in the treatment of Dementia with lewy bodies. The American 
Journal of Geriatric Psychiatry 2004;12(5):542-3 
 
Not a disease 
modification trial 
Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study 
of clonidine plus physostigmine in Alzheimer's disease. Dementia 
1994;5(5):243-6 
 
Not a disease 
modification trial 
Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP. Pentoxifylline 
in cerebrovascular dementia. Journal of the American Geriatrics Society 
1992;40(3):237-44 
 
Not a disease 
modification trial 
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. 
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 
24-week, multicenter, international, randomized, placebo-controlled clinical 
trial. Stroke 2003;34(10):2323-30 
 
Not a disease 
modification trial 
Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo-
controlled, multicenter study to evaluate the safety and tolerability of 
metrifonate in patients with probable Alzheimer disease. The Metrifonate 
Study Group. Alzheimer Disease & Associated Disorders 2000;14(1):39-45 
 
Not a disease 
modification trial 
Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of 
butyrylcholinesterase genotype on the response to rivastigmine or donepezil in 
younger patients with Alzheimer's disease. Pharmacogenetics and Genomics 
2006;16(11):771-4 
 
Not a disease 
modification trial 
Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S 
Galantamine provides sustained benefits in patients with 'advanced moderate' 
Alzheimer's disease for at least 12 months Dementia & Geriatric Cognitive 
Disorders 2003;15(2):79-87 
 
Not a disease 
modification trial 
Boada-Rovira M. [Human Albumin Grifols 5% in plasmapheresis: a new therapy 
involving beta-amyloid mobilisation in Alzheimer's disease]. Revista de 
neurologia 2010;50(Suppl 5):S9-18 
 
Full text unavailable in 
English 
Boada-Rovira M, Lopez O, Nunez L, Ortiz P, Anaya F, Hernandez I, et al. A phase 
II study to evaluate the efficacy and safety of plasma replacement with 5% 
albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its 
effects in patients with mildmoderate Alzheimer's disease. Alzheimer's & 
dementia 2014;10:P274 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects 
of xanomeline, a selective muscarinic receptor agonist, on cognitive function 
and behavioral symptoms in Alzheimer disease. Archives of neurology 
1997;54(4):465-73 
 
Not a disease 
modification trial 
Bogaert P, Grinsven R, Tolson D, Wouters K, Engelborghs S, Mussele S. Effects 
of SolCos model-based individual reminiscence on older adults with mild to 
moderate dementia due to Alzheimer disease: a pilot study. Journal of the 
American Medical Directors Association 2013;14(7):528 
 
Not a disease 
modification trial 
Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, et al. Decreased 
activation along the dorsal visual pathway after a 3-month treatment with 
Not a disease 
modification trial 
Reference Reason for exclusion 
galantamine in mild Alzheimer disease: A functional magnetic resonance 
imaging study. Journal of Clinical Psychopharmacology 2009;29(2):147-56 
 
Bottino CMC, Carvalho IAM, Alvarez AMM, Avila R, Zukauskas PR, Bustamante 
SEZ, et al. Cognitive rehabilitation combined with drug treatment in 
Alzheimer's disease patients: a pilot study. Clinical Rehabilitation 
2005;19(8):861-9 9 
 
Not a disease 
modification trial 
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A 
randomized, multicenter, placebo controlled trial of memantine for behavioral 
variant ftd and semantic variant PPA. Alzheimers Dement 2012;1:P405 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A 
26-week, multicenter, randomized, double blind, placebo controlled trial of 
memantine for behavioral variant FTD and semantic variant PPA. Dementia 
and geriatric cognitive disorders 2012;34:47-8  
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, et 
al. Memantine in patients with frontotemporal lobar degeneration: a 
multicentre, randomised, double-blind, placebo-controlled trial. The Lancet 
Neurology 2013;12(2):149-56 
 
Not a disease 
modification trial 
Boxer A, Tartaglia M, Koestler M, Lasky A, Fine E, Heuer H, et al. A 12 week, 
randomized, double-blind, placebo-controlled pilot clinical trial of davunetide 
15 mg intranasally twice daily for FTLD with predicted tau pathology 
(CBD,PNFA, PSP). Dementia and Geriatric Cognitive Disorders 2010;30:28-9 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
Breeze RW, Cox S, Rodgers-Cox J. Changes in P-300 latency as a result of co-
dergocrine mesylate therapy in patients with senile dementia. International 
journal of geriatric psychiatry 1988;3(4):263-6 
 
Not a disease 
modification trial 
Brem A-K, Atkinson NJ, Seligson EE, Pascual-Leone A. Differential 
pharmacological effects on brain reactivity and plasticity in Alzheimer's 
disease. Frontiers in Psychiatry 2013;4:124 
 
Not a disease 
modification trial 
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. Effects 
of cognitive training and rtms in Alzheimer's disease. Alzheimers Dement 
2013;1:664 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. 
Synergistic effects of rTMS and cognitive training in Alzheimer's Disease. 
Journal of the Neurological Sciences 2013;333:e343 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. 
Galantamine prolonged-release formulation in the treatment of mild to 
moderate Alzheimer's disease. Dementia and geriatric cognitive disorders 
2005;20(2-3):120-32 
 
Not a disease 
modification trial 
Brooks JO, 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in 
younger patients with Alzheimer's disease: a reanalysis of a double-blind, 
placebo-controlled study using the trilinear approach. International 
Psychogeriatrics 1998;10(2):193-203 
 
Not a disease 
modification trial 
Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. 
Development of an exercise intervention to improve cognition in people with 
Not a disease 
modification trial 
Reference Reason for exclusion 
mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, 
registration ISRCTN32612072 Physiotherapy 2015;101(2):126-34 
 
Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, et al. Effect of age 
on response to rivastigmine or donepezil in patients with Alzheimer's disease. 
Current Medical Research & Opinion 2006;22(3):483-94 
 
Not a disease 
modification trial 
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. 
Rivastigmine and donepezil treatment in moderate to moderately-severe 
Alzheimer's disease over a 2-year period. Current Medical Research & Opinion 
2005;21(8):1317-27 
 
Not a disease 
modification trial 
Burgener SC, Yang Y, Gilbert R, Marsh-Yant S. The effects of a multimodal 
intervention on outcomes of persons with early-stage dementia American. 
Journal of Alzheimer's Disease & Other Dementias 2008;23(4):382-94 
 
Not a disease 
modification trial 
Burke D. Donepezil or memantine improved cognitive functioning in moderate-
to-severe Alzheimer disease. ACP Journal Club 2012;156(6):1 
 
Not published in a peer 
reviewed journal article 
or an ongoing trial 
 
Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK. L-
deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary 
results. Journal of the American Geriatrics Society 1993;41(4):367-70 
 
Not a disease 
modification trial 
Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-
deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 
15-month trial. Journal of the American Geriatrics Society 1993;41(11):1219-25 
 
Not a disease 
modification trial 
Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of 
rivastigmine in patients with and without visual hallucinations in dementia 
associated with Parkinson's disease. Movement Disorders 2006;21(11):1899-
907 
 
Not a disease 
modification trial 
Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: 
an open-label, multicentre study in patients with Alzheimer's disease. 
International journal of geriatric psychiatry 2007;22(8):806-12  
 
Not a disease 
modification trial 
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of 
donepezil in Alzheimer's disease - results from a multinational trial Dementia & 
Geriatric Cognitive Disorders 1999;10(3):237-44 
 
Not a disease 
modification trial 
Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with 
moderately severe Alzheimer's disease. International Journal of Geriatric 
Psychiatry 2004;19(3):243-9 
 
Not a disease 
modification trial 
Burns A GS, Perdomo C. Long-term use of donepezil may be safe and effective 
in elderly AD patients. Brown University Geriatric Psychopharmacology Update 
2007;11(10):3-4 
 
Not a disease 
modification trial 
Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, et al. 
Effects of a newly developed cognitive intervention in amnestic mild cognitive 
impairment and mild Alzheimer's disease: A pilot study. Journal of Alzheimer's 
Disease 2011;25(4):679-94 
 
Not a disease 
modification trial 
Reference Reason for exclusion 
Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. 
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-
blind, phase 2 trial. Neurology 2015;84(21):2161-8 
 
Not a disease 
modification trial 
Camargo CH, Justus FF, Retzlaff G. The effectiveness of reality orientation in 
the treatment of Alzheimer's disease American. Journal of Alzheimer's Disease 
& Other Dementias 2015;30(5):527-32 
 
Not a disease 
modification trial 
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M. Effects of 
Gingko biloba supplementation in Alzheimer's disease patients receiving 
cholinesterase inhibitors: Data from the ICTUS study. Phytomedicine 
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